News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
416,247 Results
Type
Article (18782)
Company Profile (311)
Press Release (397154)
Section
Business (133788)
Career Advice (606)
Deals (23762)
Drug Delivery (42)
Drug Development (58824)
Employer Resources (60)
FDA (8905)
Job Trends (8284)
News (223576)
Policy (16209)
Tag
Academia (1262)
Alliances (31918)
Alzheimer's disease (828)
Approvals (8862)
Artificial intelligence (69)
Bankruptcy (181)
Best Places to Work (6601)
Biotechnology (259)
Breast cancer (74)
Cancer (720)
Career advice (520)
Cell therapy (169)
Clinical research (46698)
Collaboration (243)
Compensation (119)
COVID-19 (1245)
C-suite (77)
Cystic fibrosis (64)
Data (737)
Diabetes (73)
Diagnostics (3132)
Earnings (53371)
Employer resources (58)
Events (70732)
Executive appointments (214)
FDA (9214)
Funding (245)
Gene therapy (136)
GLP-1 (386)
Government (1507)
Healthcare (10360)
Infectious disease (1280)
Inflammatory bowel disease (92)
Interviews (74)
IPO (11728)
Job creations (1922)
Job search strategy (483)
Layoffs (283)
Legal (3682)
Lung cancer (115)
Manufacturing (85)
Medical device (6178)
Medtech (6181)
Mergers & acquisitions (12108)
Metabolic disorders (244)
Neuroscience (1017)
NextGen Class of 2024 (3441)
Non-profit (1739)
Northern California (995)
Obesity (145)
Opinion (126)
Parkinson's disease (58)
People (40866)
Phase I (15653)
Phase II (21140)
Phase III (14539)
Pipeline (270)
Postmarket research (1358)
Preclinical (6541)
Press Release (68)
Radiopharmaceuticals (226)
Rare diseases (155)
Real estate (3133)
Regulatory (11760)
Research institute (1286)
Resumes & cover letters (84)
Southern California (902)
Startups (2542)
United States (8772)
Vaccines (189)
Weight loss (94)
Date
Today (184)
Last 7 days (799)
Last 30 days (2451)
Last 365 days (25976)
2024 (22840)
2023 (28958)
2022 (37081)
2021 (39021)
2020 (35060)
2019 (26241)
2018 (19892)
2017 (20633)
2016 (18652)
2015 (22850)
2014 (17707)
2013 (13883)
2012 (14723)
2011 (15238)
2010 (14749)
Location
Africa (341)
Arizona (86)
Asia (24131)
Australia (3756)
California (2244)
Canada (887)
China (148)
Colorado (89)
Connecticut (102)
Europe (52623)
Florida (265)
Georgia (66)
Illinois (179)
Indiana (82)
Kansas (69)
Maryland (326)
Massachusetts (1892)
Michigan (98)
Minnesota (152)
New Jersey (639)
New York (650)
North Carolina (512)
Northern California (995)
Ohio (98)
Pennsylvania (485)
South America (477)
Southern California (902)
Texas (266)
Washington State (239)
416,247 Results for "boehringer mannheim corporation therapeutics division bmct".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Boehringer Buys Nerio Therapeutics for $1.3B to Boost Immuno-Oncology Pipeline
Under the deal announced Monday with the California biotech, German pharma Boehringer Ingelheim is gaining access to novel immune checkpoint inhibitors designed to activate the immune system to fight cancer cells.
July 29, 2024
·
2 min read
·
Tyler Patchen
Drug development
Boehringer, Insilico Appear to Break Through Against IPF
Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary fibrosis, an intractable lung disease for which current treatment options fail to stop progression, but the data were limited, leaving experts wanting.
September 24, 2024
·
4 min read
·
Heather McKenzie
Phase III
Boehringer Aces Phase III Pulmonary Fibrosis Trial, Plans FDA Application
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and inflammation in the lungs, met its primary endpoint in a late-stage study.
September 17, 2024
·
2 min read
·
Tristan Manalac
Business
QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments
QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim.
June 4, 2024
·
3 min read
Drug Development
MASH Clash Between Lilly and Boehringer-Zealand Takes Center Stage at EASL24
Both Eli Lilly and the partnered companies Boehringer Ingelheim and Zealand Pharma have mid-stage data readouts this week, fueling the race in metabolic dysfunction-associated steatohepatitis.
June 7, 2024
·
3 min read
·
Greg Slabodkin
Biosimilars
Boehringer Ingelheim Partners With GoodRx to Offer Humira Biosimilar at 92% Discount
In a bid to take advantage of Humira’s slow loss of market share, Boehringer Ingelheim is offering its biosimilar at a 92% discount exclusively to patients who buy the product on GoodRx.
July 19, 2024
·
2 min read
·
Tristan Manalac
Biotech Bay
Boehringer Ingelheim expands access to adalimumab-adbm injection, the company’s biosimilar to Humira®
Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s biosimilar to Humira®, in the U.S.
May 13, 2024
·
11 min read
Press Releases
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
September 16, 2024
·
6 min read
Business
PhoreMost Achieves Second Milestone in Target Discovery Alliance with Boehringer Ingelheim
PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim.
June 3, 2024
·
2 min read
FDA
FDA Approval Fuels Boehringer’s Biosimilar Challenge to AbbVie’s Humira
Boehringer Ingelheim on Wednesday won the FDA’s approval for a high-concentration and citrate-free version of its Humira biosimilar Cyltezo, targeting AbbVie’s blockbuster drug.
May 2, 2024
·
2 min read
·
Tristan Manalac
1 of 41,625
Next
